These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 36439169)
1. Non-replicative antibiotic resistance-free DNA vaccine encoding S and N proteins induces full protection in mice against SARS-CoV-2. Alcolea PJ; Larraga J; Rodríguez-Martín D; Alonso A; Loayza FJ; Rojas JM; Ruiz-García S; Louloudes-Lázaro A; Carlón AB; Sánchez-Cordón PJ; Nogales-Altozano P; Redondo N; Manzano M; Lozano D; Palomero J; Montoya M; Vallet-Regí M; Martín V; Sevilla N; Larraga V Front Immunol; 2022; 13():1023255. PubMed ID: 36439169 [TBL] [Abstract][Full Text] [Related]
2. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection. Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J Front Immunol; 2021; 12():824728. PubMed ID: 35154086 [TBL] [Abstract][Full Text] [Related]
3. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection. Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J Front Immunol; 2022; 13():995235. PubMed ID: 36172368 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate. Perdiguero B; Marcos-Villar L; López-Bravo M; Sánchez-Cordón PJ; Zamora C; Valverde JR; Sorzano CÓS; Sin L; Álvarez E; Ramos M; Del Val M; Esteban M; Gómez CE Front Immunol; 2023; 14():1160065. PubMed ID: 37404819 [TBL] [Abstract][Full Text] [Related]
5. Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infection. Gómez-Carballa A; Albericio G; Montoto-Louzao J; Pérez P; Astorgano D; Rivero-Calle I; Martinón-Torres F; Esteban M; Salas A; García-Arriaza J Antiviral Res; 2023 Dec; 220():105760. PubMed ID: 37992765 [TBL] [Abstract][Full Text] [Related]
6. Gold-Nanostar-Chitosan-Mediated Delivery of SARS-CoV-2 DNA Vaccine for Respiratory Mucosal Immunization: Development and Proof-of-Principle. Kumar US; Afjei R; Ferrara K; Massoud TF; Paulmurugan R ACS Nano; 2021 Nov; 15(11):17582-17601. PubMed ID: 34705425 [TBL] [Abstract][Full Text] [Related]
9. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge. Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964 [TBL] [Abstract][Full Text] [Related]
10. The antibiotic resistance-free mammalian expression plasmid vector pPAL for development of third generation vaccines. Alcolea PJ; Alonso A; Larraga V Plasmid; 2019 Jan; 101():35-42. PubMed ID: 30529129 [TBL] [Abstract][Full Text] [Related]
11. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa. Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842 [TBL] [Abstract][Full Text] [Related]